Latest

Semaglutide

·July 29, 2026·8 min read

Oral Ozempic Cuts Heavy Drinking and Cravings

Oral semaglutide reduces heavy drinking days, daily cravings, and alcohol-related problems in adults with Alcohol Use Disorder.

Featured Neuroscience

·May 22, 2026·8 min read

Study Aims to Break GLP-1 Weight-Loss Plateaus

The weight-loss effects of semaglutide depend on boosting a signaling molecule called cAMP within appetite-regulating neurons in the area postrema.

Featured Neurology Neuroscience

·April 23, 2026·8 min read

GLP-1 Drugs Target the Roots of Dementia

A comprehensive review of 30 studies finds that GLP-1 receptor agonists are effective at tackling the biological drivers of Alzheimer’s disease.

Featured Genetics Neuroscience

·April 8, 2026·8 min read

Ozempic Weight Loss Success Varies by DNA

A new study of 28,000 people identifies genetic markers in the GLP1R and GIPR genes that explain why some patients lose more weight or experience more nausea on GLP-1 drugs.

Featured Neuroscience

·March 10, 2026·13 min read

Why GLP-1 Drugs Affect Men and Women Differently

A new atlas reveals that GLP-1—the backbone of blockbuster weight-loss drugs—is mapped differently in the male and female brain.

This shows a woman holding her head in pain.

Featured Neurology Neuroscience

·March 2, 2026·7 min read

Beyond Weight Loss: Ozempic Linked to Migraine Reduction

Unexpected relief. New research shows that patients taking GLP-1 drugs for diabetes or weight loss also experience fewer emergency room visits and need fewer medications for their chronic migraines.

Featured Neuroscience

·May 26, 2025·4 min read

Brainstem Neurons Hold Key to Semaglutide’s Weight Loss Effects

Researchers have identified a specific group of brainstem neurons that mediate the appetite-reducing and weight-loss effects of semaglutide without triggering side effects like nausea. In mice, activating these neurons led to reduced food intake and fat loss, mimicking the drug’s benefits.

Featured Neuroscience

·May 13, 2025·6 min read

Zepbound Outperforms Wegovy in Head-to-Head Weight Loss Trial

In a 72-week clinical trial, tirzepatide (Zepbound) led to significantly greater weight loss than semaglutide (Wegovy), with participants losing an average of 20.2% of their body weight versus 13.7%. The study directly compared the two drugs at their highest doses in people with obesity but without diabetes.

Featured Neuroscience

·February 12, 2025·7 min read

Semaglutide Shows Promise in Reducing Alcohol Cravings and Consumption

A new study suggests that semaglutide, a drug commonly used for diabetes and obesity, may also help reduce alcohol consumption. Researchers found that weekly injections of semaglutide decreased alcohol cravings, drinking quantity, and heavy drinking days in adults with alcohol use disorder. Participants receiving semaglutide consumed less alcohol in a controlled lab setting and reported reduced cravings compared to those receiving a placebo.

Featured Neurology Neuroscience

·October 24, 2024·4 min read

Ozempic Shows Potential in Lowering Alzheimer’s Risk

New research suggests that semaglutide, a popular diabetes and weight-loss drug, may reduce the risk of Alzheimer’s disease in people with type 2 diabetes. The study compared semaglutide to seven other anti-diabetic drugs and found it was linked to a significantly lower risk of developing Alzheimer’s.

Featured Neurology Neuroscience

·October 6, 2024·5 min read

Study Finds Wegovy Reduces COVID-19 Death Risk by One-Third

A new trial reveals that weekly injections of the weight-loss drug Wegovy (semaglutide) lowered the risk of death from COVID-19 by about a third and reduced overall mortality by 19%. The study followed more than 17,000 participants with heart disease and obesity, showing that Wegovy decreased the likelihood of death from cardiovascular disease by 15% and other causes by 23%.

Featured Neurology Neuroscience

·July 12, 2024·5 min read

Ozempic Reduces Dementia Risk, Curbs Nicotine Cravings

A new study finds that semaglutide, known as Ozempic/Wegovy, does not negatively impact brain health and may reduce cognitive problems and nicotine dependence. The analysis, using over 100 million patient records, revealed no increased risk of neurological or psychiatric conditions compared to other antidiabetic medications. These findings suggest semaglutide's benefits may extend beyond diabetes management. Further research is needed to confirm these potential benefits.

1 2

Semaglutide

Oral Ozempic Cuts Heavy Drinking and Cravings

Study Aims to Break GLP-1 Weight-Loss Plateaus

GLP-1 Drugs Target the Roots of Dementia

Ozempic Weight Loss Success Varies by DNA

Why GLP-1 Drugs Affect Men and Women Differently

Beyond Weight Loss: Ozempic Linked to Migraine Reduction

Brainstem Neurons Hold Key to Semaglutide’s Weight Loss Effects

Zepbound Outperforms Wegovy in Head-to-Head Weight Loss Trial

Semaglutide Shows Promise in Reducing Alcohol Cravings and Consumption

Ozempic Shows Potential in Lowering Alzheimer’s Risk

Study Finds Wegovy Reduces COVID-19 Death Risk by One-Third

Ozempic Reduces Dementia Risk, Curbs Nicotine Cravings

How Severe Illness During Pregnancy Alters Fetal Brain Development

Aging Brains Maintain Robust Language Networks Despite Cognitive Decline

Youth Protein TIMP2 Restores Immune Function in the Aging Brain

Shame, Stigma, and Culture Prevent Male Domestic Violence Survivors From Seeking Help

Subscribe